-
Trifluoperazine 2HCl in D2 Research
2026-08-31
Trifluoperazine 2HCl combines nanomolar dopamine D2 receptor inhibition with practical utility in receptor, macrophage, and exploratory cancer assays. This guide turns its solubility and pharmacology profile into reproducible workflows, controls, and troubleshooting decisions.
-
Decitabine Workflow for Cancer Epigenetics
2026-08-31
Decitabine provides a practical dose window for separating DNA hypomethylation from overt cytotoxicity in hematopoietic and solid-tumor models. This workflow also adapts immune-homeostasis findings from patient and mouse studies to improve assay design, combination studies, and troubleshooting.
-
CAF–ANGPTL4–IQGAP1 Signaling in Prostate Cancer
2026-08-30
This study identifies a paracrine CAF–ANGPTL4–IQGAP1 axis that reprograms prostate cancer cells toward mitochondrial biogenesis and oxidative phosphorylation, reducing chemotherapy sensitivity. Its integrated secretome, metabolic, protein-interaction, and pharmacologic analyses nominate IQGAP1 and CAF-derived ANGPTL4 as testable intervention points, although clinical validation remains necessary.
-
HyperFluor 488 Goat Anti-Rabbit IgG Guide
2026-08-29
HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody provides fluorescent detection of rabbit primary antibodies in immunofluorescence, immunocytochemistry, flow cytometry, and related microscopy workflows. It should not be used with non-rabbit primary antibodies or protocols incompatible with its sodium azide-containing formulation.
-
Z17 Restores Astrocyte Amyloid Clearance via CHI3L1
2026-08-28
The reference study identifies Compound Z17 as a selective CHI3L1 binder that suppresses inflammatory NF-κB signaling while restoring amyloid-β handling and lysosomal activity in human iPSC-derived astrocytes. Its findings connect CHI3L1 inhibition with functional astrocyte repair, although the evidence remains primarily in vitro and requires validation in disease-relevant animal and clinical models.
-
MK 0893: From Allostery to Assay Design
2026-08-28
MK 0893 is a glucagon receptor antagonist with a distinctive extra-helical mechanism and nanomolar activity. This guide translates its pharmacology into practical assay design, selectivity analysis, and diabetes-model interpretation.
-
HRP Goat Anti-Mouse IgG (H+L) Antibody Guide
2026-08-27
HRP Goat Anti-Mouse IgG (H+L) Antibody, SKU K1221, provides an HRP-labeled secondary reagent for detecting mouse IgG primary antibodies in Western blotting, ELISA, IHC, and ICC. It should not be treated as a universal secondary antibody or used without optimization for non-mouse primary antibodies, mouse tissues, or assays requiring fluorescence.
-
Sodium Oxamate: Mapping Lactate-Linked Signaling
2026-08-27
Sodium Oxamate is more than an LDH-A inhibitor: it can help separate glycolytic flux from lactate-dependent signaling. This article develops a cross-domain assay framework linking cancer metabolism research with emerging evidence on BVDV immune evasion while clearly defining experimental limits.
-
Glycogen Colorimetric Assay Kit II for Metabolic Studies
2026-08-26
The Glycogen Colorimetric Assay Kit II converts glycogen to a measurable glucose-derived color signal, supporting sensitive analysis in tissue, disease, exercise, and circadian studies. Its interference-aware design and plate-compatible workflow are especially useful when reducing substances complicate conventional oxidase-based measurements.
-
Abiraterone Acetate in 3D Prostate Cancer Models
2026-08-26
Learn how to deploy Abiraterone acetate as a CYP17 inhibitor in two-dimensional assays and patient-derived prostate cancer spheroids. This workflow emphasizes model selection, solvent control, androgen receptor activity inhibition, comparative drug testing, and troubleshooting when three-dimensional cultures show limited response.
-
Cell Lysis Buffer for WB and IP in CAF Research
2026-08-25
Cell lysis buffer for WB and IP can help preserve phosphorylation states and native protein associations when dissecting CAF-driven chemoresistance. This guide maps lysis chemistry to ANGPTL4-IQGAP1 pathway assays, controls, and interpretation limits.
-
Dextrose (D-glucose) in Metabolism Research
2026-08-25
Dextrose, or D-glucose, is a defined monosaccharide substrate for glucose metabolism research, cell culture media supplementation, and cellular energy production studies. Its value in hypoxia and immunometabolism experiments is greatest when concentration, solvent, storage, and biological context are controlled separately.
-
Hypoxia-Activated BNNC Targets Cyclin K in Cancer
2026-08-24
The reference study introduces BNNC, a hypoxia-activated photomolecular glue designed to release the Cyclin K degrader (R)-CR8 together with the phototherapeutic agent BSS-Et in tumors. Cell and animal results indicate that coordinated Cyclin K degradation, DNA damage, and phototherapy can improve antitumor activity while preserving tumor-selective design logic.
-
FK866 (APO866): Mapping NAMPT Dependence Beyond AML
2026-08-24
FK866 (APO866) offers a precise way to interrogate NAMPT dependence, NAD depletion, mitochondrial stress, and selective vulnerability in hematologic cancer models. This thought-leadership analysis connects AML research with emerging evidence that NAMPT also governs DNA-damage responses and cellular aging, while defining the experimental controls needed for credible translation.
-
Necrostatin-1: RIP1 Kinase Workflow Guide
2026-08-23
Build cleaner necroptosis assays with Necrostatin-1, from TNF-α challenge experiments to virus–host and tissue-injury models. This guide connects RIP1 kinase inhibition with RIPK3/MLKL validation and practical troubleshooting for cell and acute kidney injury (AKI) research.